Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 96

1.

Maximum tumor diameter as a predictor for outcome following salvage radiation for prostate cancer.

Jackson WC, Song Y, Foster B, Li D, Foster C, Palapattu GS, Mehra R, Kunju P, Feng FY, Hamstra DA.

J Clin Oncol. 2013 Feb 20;31(6_suppl):78. doi: 10.1200/jco.2013.31.6_suppl.78.

PMID:
28137099
2.

Gleason pattern 5 as a pathologic predictor of recurrence, development of metastasis, and prostate cancer-specific death for patients receiving salvage radiation therapy following radical prostatectomy.

Johnson SB, Foster C, Li D, Foster B, Song Y, Sandler HM, Palapattu GS, Kunju P, Mehra R, Hamstra DA, Feng FY.

J Clin Oncol. 2013 Feb 20;31(6_suppl):151. doi: 10.1200/jco.2013.31.6_suppl.151.

PMID:
28136734
3.

PSA doubling time of ≤6 months as the optimal cutoff for predicting clinically relevant outcomes for men receiving salvage radiation therapy post radical prostatectomy.

Johnson SB, Foster B, Foster C, Song Y, Li D, Sandler HM, Palapattu GS, Hamstra DA, Feng FY.

J Clin Oncol. 2013 Feb 20;31(6_suppl):167. doi: 10.1200/jco.2013.31.6_suppl.167.

PMID:
28136719
4.

Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma.

Skala SL, Liu TY, Udager AM, Weizer AZ, Montgomery JS, Palapattu GS, Siddiqui J, Cao X, Fields K, Abugharib AE, Soliman M, Hafez KS, Miller D, Lee CT, Alva A, Chinnaiyan AM, Morgan TM, Spratt DE, Jiang H, Mehra R.

Eur Urol Focus. 2016 Dec 13. pii: S2405-4569(16)30169-9. doi: 10.1016/j.euf.2016.11.011. [Epub ahead of print]

PMID:
28753826
5.

Diagnostic accuracy of the PROMIS study.

Salami SS, George AK, Montgomery JS, Morgan TM, Palapattu GS.

Lancet. 2017 Jul 22;390(10092):362. doi: 10.1016/S0140-6736(17)31598-2. No abstract available.

PMID:
28745602
6.

Genomic Tests Should be Used to Help Guide Treatment of Prostate Cancer: Yes.

Palapattu GS.

J Urol. 2017 Jun 16. pii: S0022-5347(17)67196-9. doi: 10.1016/j.juro.2017.05.039. [Epub ahead of print] No abstract available.

PMID:
28629664
7.

Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer.

Palapattu GS, Salami SS, Cani AK, Hovelson DH, Lazo de la Vega L, Vandenberg KR, Bratley JV, Liu CJ, Kunju LP, Montgomery JS, Morgan TM, Natarajan S, Huang J, Tomlins SA, Marks LS.

Clin Cancer Res. 2017 Feb 15;23(4):985-991. doi: 10.1158/1078-0432.CCR-16-1454. Epub 2016 Oct 7.

PMID:
28031426
8.

Potential Implications of Shortening Length of Stay Following Radical Cystectomy in a Pre-ERAS Population.

Osawa T, Ambani SN, Olugbade K Jr, Skolarus TA, Weizer AZ, Montgomery JS, He C, Hafez KS, Hollenbeck BK, Lee CT, Montie JE, Palapattu GS, Morgan TM.

Urology. 2017 Apr;102:92-99. doi: 10.1016/j.urology.2016.10.051. Epub 2016 Dec 21.

PMID:
28013038
9.

Reporting standards for the imaging-based diagnosis of renal masses on CT and MRI: a national survey of academic abdominal radiologists and urologists.

Davenport MS, Hu EM, Smith AD, Chandarana H, Hafez K, Palapattu GS, Stuart Wolf J Jr, Silverman SG; Society of Abdominal Radiology Disease Focused Panel on Renal Cell Carcinoma.

Abdom Radiol (NY). 2017 Apr;42(4):1229-1240. doi: 10.1007/s00261-016-0962-x.

PMID:
27878338
10.

A rare case of bilateral synchronous spermatocytic tumours in a young man seeking fertility preservation.

Østergren P, Salami SS, Udager A, Sønksen J, Ohl D, Palapattu GS.

Scand J Urol. 2017 Feb;51(1):78-80. doi: 10.1080/21681805.2016.1249515. Epub 2016 Nov 4.

PMID:
27809692
11.

Predictors of Delayed Intervention for Patients on Active Surveillance for Small Renal Masses: Does Renal Mass Biopsy Influence Our Decision?

Ambani SN, Morgan TM, Montgomery JS, Gadzinski AJ, Jacobs BL, Hawken S, Krishnan N, Caoili EM, Ellis JH, Kunju LP, Hafez KS, Miller DC, Palapattu GS, Weizer AZ, Wolf JS Jr.

Urology. 2016 Dec;98:88-96. doi: 10.1016/j.urology.2016.04.067. Epub 2016 Jul 19.

PMID:
27450936
12.

Independent surgical validation of the new prostate cancer grade-grouping system.

Spratt DE, Cole AI, Palapattu GS, Weizer AZ, Jackson WC, Montgomery JS, Dess RT, Zhao SG, Lee JY, Wu A, Kunju LP, Talmich E, Miller DC, Hollenbeck BK, Tomlins SA, Feng FY, Mehra R, Morgan TM.

BJU Int. 2016 Nov;118(5):763-769. doi: 10.1111/bju.13488. Epub 2016 Apr 19.

PMID:
27009882
13.

Effect of delayed resection after initial surveillance and tumor growth rate on final surgical pathology in patients with small renal masses (SRMs).

Hawken SR, Krishnan NK, Ambani SN, Montgomery JS, Caoili EM, Ellis JH, Kunju LP, Hafez KS, Miller DC, Kutikov A, Palapattu GS, Weizer AZ, Stuart Wolf J, Morgan TM.

Urol Oncol. 2016 Nov;34(11):486.e9-486.e15. doi: 10.1016/j.urolonc.2016.05.032. Epub 2016 Sep 28.

PMID:
27687544
14.

Comparison of Percutaneous Renal Mass Biopsy and R.E.N.A.L. Nephrometry Score Nomograms for Determining Benign Vs Malignant Disease and Low-risk Vs High-risk Renal Tumors.

Osawa T, Hafez KS, Miller DC, Montgomery JS, Morgan TM, Palapattu GS, Weizer AZ, Caoili EM, Ellis JH, Kunju LP, Wolf JS Jr.

Urology. 2016 Oct;96:87-92. doi: 10.1016/j.urology.2016.05.044. Epub 2016 Jun 1.

PMID:
27262393
15.

Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches.

Udager AM, Liu TY, Skala SL, Magers MJ, McDaniel AS, Spratt DE, Feng FY, Siddiqui J, Cao X, Fields KL, Morgan TM, Palapattu GS, Weizer AZ, Chinnaiyan AM, Alva A, Montgomery JS, Tomlins SA, Jiang H, Mehra R.

Ann Oncol. 2016 Sep;27(9):1706-12. doi: 10.1093/annonc/mdw216. Epub 2016 May 23.

PMID:
27217541
16.

Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer.

Kaushik AK, Shojaie A, Panzitt K, Sonavane R, Venghatakrishnan H, Manikkam M, Zaslavsky A, Putluri V, Vasu VT, Zhang Y, Khan AS, Lloyd S, Szafran AT, Dasgupta S, Bader DA, Stossi F, Li H, Samanta S, Cao X, Tsouko E, Huang S, Frigo DE, Chan L, Edwards DP, Kaipparettu BA, Mitsiades N, Weigel NL, Mancini M, McGuire SE, Mehra R, Ittmann MM, Chinnaiyan AM, Putluri N, Palapattu GS, Michailidis G, Sreekumar A.

Nat Commun. 2016 May 19;7:11612. doi: 10.1038/ncomms11612.

17.

Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy.

Kozminski MA, Tomlins S, Cole A, Singhal U, Lu L, Skolarus TA, Palapattu GS, Montgomery JS, Weizer AZ, Mehra R, Hollenbeck BK, Miller DC, He C, Feng FY, Morgan TM.

Urol Oncol. 2016 Sep;34(9):415.e1-6. doi: 10.1016/j.urolonc.2016.03.019. Epub 2016 Apr 29.

PMID:
27140065
18.

Categorizing renal oncocytic neoplasms on core needle biopsy: a morphologic and immunophenotypic study of 144 cases with clinical follow-up.

Alderman MA, Daignault S, Wolf JS Jr, Palapattu GS, Weizer AZ, Hafez KS, Kunju LP, Wu AJ.

Hum Pathol. 2016 Sep;55:1-10. doi: 10.1016/j.humpath.2016.03.017. Epub 2016 Apr 13.

PMID:
27085554
20.

Parsing Multi-omic Data to Understand Urothelial Cell Carcinoma Progression.

Palapattu GS.

J Urol. 2016 Jun;195(6):1645. doi: 10.1016/j.juro.2016.02.2965. Epub 2016 Mar 2. No abstract available.

PMID:
26946160

Supplemental Content

Loading ...
Support Center